<DOC>
	<DOCNO>NCT01308294</DOCNO>
	<brief_summary>The purpose study determine whether vaccination tumor antigenic peptide IMP321/LAG-3 Montanide adjuvants induce immune response melanoma patient assess safety tolerability vaccination . Tumor responses follow vaccination also document .</brief_summary>
	<brief_title>Immunotherapy HLA-A2 Positive Stage II-IV Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm stage II , III IV melanoma patient . Tumor expression MelanA . Human leukocyte antigenA2 ( HLAA2 ) positive . Expected survival list 3 month . Karnofsky scale performance status 70 % . Age ≥ 18 year . Able give write informed consent . The following laboratory result : Hemoglobin ≥ 100g/L Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 100 x 109/L Serum creatinine ≤ 2 mg/dL ( 0.18mmol/L ) Serum bilirubin ≤ 2mg/dL ( 0.034mmol/L ) Granulocyte count &gt; 2.5x109/L ASAT , ALAT &lt; 2.5 x upper limit normal aPTT within normal range ±25 % TP ≥ 80 % Clinically significant heart disease . Serious illness , eg . serious infection require antibiotic , uncontrolled peptic ulcer , central nervous system disorder . History immunodeficiency disease autoimmune disease . Metastatic disease central nervous system , unless treat stable . Known HIV positivity . Known seropositivity hepatitis B surface antigen . Concomitant treatment steroid , antihistamine drug . Topical inhalation steroid permit . Participation clinical trial involve another investigational agent within 4 week prior enrollment . Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception . Psychiatric addictive disorder may compromise ability give informed consent . Lack availability patient immunological clinical followup assessment . Coagulation bleed disorder . Kidney dysfunction creatinine &gt; 2 X upper limit normal value . Reported strong ( allergic ) reaction previous vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Stage II-IV</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccination</keyword>
	<keyword>HLA class I II tumor-specific peptide</keyword>
	<keyword>IMP321</keyword>
	<keyword>Montanide ISA-51 VG</keyword>
</DOC>